Inbrija Can Help to Improve Work Productivity and Keep Dyskinesia at Bay, Acorda Reports

study data presentations

Use of Inbrija (levodopa inhalation powder) and like medications help to more effectively manage of off episodes in Parkinson’s disease and improve work productivity in patients using it, according to a study being presented by Acorda Therapeutics at the International Congress of Parkinson’s Disease and Movement Disorders.

Another study presentation at the congress, now underway in France, will show that Inbrija treatment does not lead to a worsening of dyskinesia, or involuntary muscle movement.

Dopaminergic medications, like levodopa, help to control Parkinson’s motor symptoms. But as disease progresses, patients typically need to gradually increase their dose to maintain the same level of benefit. And even with such increases, they sometimes experience a reappearance or worsening of symptoms (off periods) due to the diminishing effects of dopaminergic therapy.

In the study, “Impact of OFF periods on aspects of employment for people with Parkinson’s disease,” presented as a scientific poster, researchers characterized the burden of off periods on work absence and productivity.

They used data from the “Financial and Social Impact of Parkinson’s Disease Survey” produced by the Michael J. Fox Foundation (MJFF) and the Parkinson’s Foundation, conducted between Sept. 17 and Oct. 8, 2018.

The online survey was directed at people with Parkinson’s, and completed by the patients, their care partners, family members or close friends. It compared the burden — in terms of work productivity — of off periods in people reporting to experience them in the past 12 months to those reporting no experience of off periods while on dopaminergic therapy.

A total 1,602 surveys were returned, 70% completed by Parkinson’s patients, and 20% by caregivers, family members, or close friend. Off periods were reported by 881 (55%) survey respondents, and an absence of off-period symptoms by 434 (27%) . Around 18% (287 people) did not know if they had experienced an off period over the previous year or failed to respond to the question.

Of the 881 patients reporting off periods, 176 (20%) worked full or part-time. Among those without such reports,  in 90 (21%) worked full or part-time. Those with off periods were more likely to report reduced work productivity, in comparison to the other patient group (72% vs. 43%).

Almost half (48%) of patients with off periods reported at least 10 days each month of low productivity, compared to the 29% of those without off period. Importantly, 34% of them missed, on average, at least three working days each month because of their disease, compared to the 21% of patients without off periods.

“PD [Parkinson’s disease] can have a financial burden on patients and their families,” the researchers noted. “More effective management of OFF periods and other PD symptoms may alleviate this burden on people with PD.”

In another scientific poster, titled “Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder),” the company summarized the results of their analysis on the effects of Inbrija (CVT-301) on Parkinson’s dyskinesia  (involuntary muscle movements).

Inbrija, developed and marketed by Acorda, is an inhaled formulation of levodopa approved by the U.S. Food and Drug Administration (FDA) to treat symptoms of Parkinson’s disease during off episodes. When inhaled, this dry powder formulation of levodopa bypasses the digestive system and to deliver a higher and more consistent dose of levodopa to the brain.

In a 12-week, randomized and placebo-controlled Phase 3 study (known as SPAN-PD, NCT02240030) in 339 Parkinson’s patients on a carbidopa/levodopa regimen and experiencing off episodes, were treated with Inbrija or placebo. Results found that treatment at an 84 mg dose significantly eased motor symptoms as soon as 30 minutes after taking a dose.

More than half of patients (58%) given Inbrija also had control of their motor symptoms, meaning they went from an off period to an on state. They also maintained an on state when evaluated up to an hour after treatment administration, compared to 36% in the placebo group.

Researchers for this study analyzed the effects of Inbrija on patients’ dyskinesia. They obtained reports made by patients taking part in the trial, required to keep diaries of time with dyskinesia, reported as occurring over three consecutive days prior to each study visit.

Adverse events during the SPAN-PD study were also examined, as were trial investigator ratings of dyskinesia occurrence and 60 minutes post-dose, measured by the Unified Parkinson’s Disease Rating Scale (UPDRS) part IV (motor complications).

On average, patients took two doses of Inbrija (84 mg) per day during the trial.

Four (3.5%) patients on Inbrija complained of a dyskinesia-like event, in contrast to none in the placebo group. No one withdrew from the study due to dyskinesia.

At week 12, examiner-rated dyskinesia at one hour post-dose was of 16.7% among Inbrija-treated patients and 8% among people in the placebo group, all rated mild to moderate with the exception of one placebo patient whose dyskinesia was judged severe.

“In this phase 3 study of [Inbrija], adverse events and examiner ratings of mild to moderate dyskinesia were reported more frequently for [Inbrija] compared to placebo, but there was no increase in troublesome dyskinesia according to the patient reported diary and the overall impact on UPDRS part IV dyskinesia score was minimal,” the researchers concluded.

The post Inbrija Can Help to Improve Work Productivity and Keep Dyskinesia at Bay, Acorda Reports appeared first on Parkinson’s News Today.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *